Product Description
Cemdomespib is the lead product candidate from Reata's Hsp90 modulator program. Cemdomespib is a highly potent and selective, oral, small molecule C-terminal modulator of Hsp90. (Sourced from: https://www.reatapharma.com/our-science/our-technologies/hsp90-modulators/default.aspx)
Mechanisms of Action: HSP90 Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Biogen
Company Location: Eastern America
Company Founding Year: 1978
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Neuropathic Pain|Neuralgia
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02666963 |
RTA 901-C-1503 | P1 |
Completed |
Healthy Volunteers |
2017-07-23 |
2024-02-02 |
||
NCT05895552 |
CYPRESS | P2 |
Terminated |
Neuropathic Pain|Neuralgia |
2024-11-15 |
28% |
2025-05-03 |
|
NCT06893094 |
CYPRESS | P2 |
Terminated |
Neuralgia|Neuropathic Pain |
2024-11-15 |
2025-03-27 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/21/2023 |
News Article |
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc. |
|
07/28/2023 |
News Article |
Biogen to Acquire Reata Pharmaceuticals |
|
06/27/2023 |
News Article |
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's Ataxia |
|
06/15/2023 |
News Article |
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement |